跳至主要内容
临床试验/KCT0001583
KCT0001583招募中未知

A Phase II trial of preoperative HER2 targeting and endocrine therapy in postmenopausal women with HER2 and HR positive breast cancer

Yonsei University Health System, Gangnam Severance Hospital0 个研究点目标入组 132 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
132

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
20(Year) 至 o Limit(—)
性别
Female

入选标准

  • 1) Patients must have histological confirmation that the patient has operable invasive breast cancer.
  • 2) Measurable lesions = 1cm
  • 3) Age = 20 years
  • 4) ECOG performance status: 0 or 1
  • 5) Postmenopausal women
  • Definition of postmenopausal
  • Age = 55 years and no history of menstruation or
  • Age < 55 years: no history of menstruation within the last 12 months and FSH(Follicle stimulating Hormone) = 30 mlU/mL
  • 6) HER2(Human Epidermal Growth factor Receptor 2) Positive
  • IHC(Immunohistochemistry) Score is 3+ or if IHC Score is 2+, (must have positive with FISH(Fluorescence in situ hybridization)/SISH(Silver enhanced in situ hybridization) tests)
  • 7) ER(Estrogen Receptor) Positive
  • Allred score = 3/8 or Modified Allred score = 4/7
  • 8) Adequate organ and bone marrow function:
  • WBC(White Blood Cell) =2.5x10^9/L
  • ANC(Absolute Neutrophil Count) =1.5x10^9/L
  • Platelet =100x10^9/L
  • Hemoglobin =10g/dl
  • Serum creatinine =1.5mg/dl
  • AST(Aspartate aminotransgerase) and ALT(Alanine aminotransferase) =2 x ULN(Upper limit of normal)
  • Alkaline phosphatase =2.5 x ULN
  • Total bilirubin =1.5mg/dl
  • 9) Adequate Cardiac Function
  • Normal ECG(Electrocardiogram) results
  • (not Consider clinically non-significant arrythmia and ischemic change as normal)
  • MUGA(Multi Gated Blood Pool Scan) or Echo(Echocardiography) shows LVEF(Left Ventricular ejection fraction) =55%
  • 10) Ability to understand a written informed consent form, and the willingness to sign it.

排除标准

  • 1) Inflammatory breast cancer
  • 2) Bilateral breast cancer
  • 3) Previous surgical history of breast cancer (excluding biopsy for diagnostic purposes)
  • 4) History of treatment for breast cancer
  • (Including hormone therapy, chemotherapy, and radiation therapy)
  • 5) History of treatment for malignant tumor other than breast cancer within last five years.
  • (Excluding treated non-melanoma skin cancer and localized cervical cancer and no evidence of recurrence of thyroid cancer for 5 years after surgery)
  • 6) Within the last six months, if the patients have any history below:
  • - Myocardial Infarction
  • - Uncontrolled or moderate cardiovascular diseases
  • - Heart failure (New York Heart Association(NYHA) Class II)
  • - Uncontrolled angina
  • - Clinically significant epicardial disease
  • - History of cardiac amyloidosis
  • 7) Presence of any severe medical condition that, in the opinion of the investigator, would limit the patients successful participation.
  • 8) Subjects who have enrolled other study and received treatment from other study within the last 4 weeks of starting of this study.

研究者

发起方
Yonsei University Health System, Gangnam Severance Hospital

相似试验

A Phase II trial of preoperative HER2 targeting and... | 临床试验